Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic - 09/11/20
Funding sources: None. |
|
Disclosure: Dr Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermavant, Dermira, Dr. Reddy's Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, UCB, and Valeant Pharmaceuticals North America LLC. Drs Kearns, Chat, and Uppal have no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
Vol 83 - N° 6
P. e433-e434 - décembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.